Bioventus Q1 Earnings Call Highlights
Key takeaways
- Operating cash flow improved to $9 million (up >$28 million YoY);
- On the call, the company also raised guidance for adjusted earnings per share and cash from operations, while reaffirming its full-year revenue outlook.
- → 3 Emerging Markets ETFs to Maximize Exposure to High-Potential Countries
Bioventus Q1 Earnings Call Highlights Market Beat Wed, May 6, 2026 at 9:55 PM GMT+7 8 min read BVS Bioventus logo Key Points Bioventus reported Q1 revenue of $132 million (up 7% Yo Y) with adjusted EBITDA of $24 million, adjusted EPS of $0.15 (vs. $0.08 a year ago) and a 76% adjusted gross margin, and it raised full-year adjusted EPS guidance to $0.75–$0.79 and cash from operations to $84–$89 million while reaffirming revenue of $600–$610 million.
Management is prioritizing revenue acceleration, earnings expansion while investing, and stronger cash flow, directing most new investment to four growth drivers—especially PNS (more than half of planned investments), plus PRP, Ultrasonics and international—with a dedicated PNS GM hired and a $13 million investment plan set to ramp through the year.
Operating cash flow improved to $9 million (up >$28 million YoY); the company ended the quarter with $36 million cash and $272 million debt after paying down $22 million, and expects net leverage to fall below 2x by end-Q2 while using free cash flow to further reduce debt.